CD86 and urogenital neoplasm: Belatacept, a selective T‐cell costimulation blocker targeting the CD80‐CD86 pathway has emerged as a potential CNI sparing alternative, particularly in kidney transplant, where it has demonstrated improved long‐term renal function and a favorable cardiovascular and metabolic profile [26, 27, 28].